Blockchain Registration Transaction Record

Optimi Health to Launch Phase 2 Psilocybin Trial for Depression

Optimi Health plans Phase 2 trial of psilocybin-assisted therapy for major depressive disorder, enrolling 200 patients in Canada. Read about this milestone.

This news matters because it signals a major step forward in the clinical validation of psilocybin as a treatment for major depressive disorder, a condition affecting millions worldwide. If successful, Optimi’s trial could pave the way for regulatory approval and broader patient access to psychedelic-assisted therapies, offering new hope for those who have not responded to conventional treatments. The company’s GMP-grade manufacturing and existing distribution channels in Australia and Canada position it as a key player in the emerging psychedelic pharmaceutical market, potentially accelerating the integration of these therapies into mainstream mental health care.